Year: 2020

Schlieren/Switzerland, 24 November 2020The news release can be downloaded from the following link:AttachmentCTOCROO_Adhoc

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month periods ended March 31, 2020 and June 30, 2020, any corresponding management’s discussion and analyses (collectively, the “Restated Documents”) will be restated and reissued.During the fiscal year ended December 31, 2019, the Company recognized intangible assets in connection with the acquisitions of Relyfe Brand, LLC, Tealief Brand, LLC, and Drink Fresh Water, LLC. Upon further review, the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as a result will be recorded as transaction costs in the Company’s...

 If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids:100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add-back therapy (ABT)200 mg once daily with concomitant ABT for long-term use (beyond 6 months)200 mg once daily for short-term use, in particular when rapid reduction in fibroid volume is desired ObsEva expects to submit a new drug application to U.S. Food and Drug Administration in 1H:21             GENEVA, Switzerland and BOSTON, MA (November 24, 2020) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)...

Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person (post-exposure prophylaxis)Roche also provides an update on the sNDA filing for Xofluza in the paediatric setting             Basel, 24 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.Attachment24112020_MR_ Xofluza US approval_ EN

Amsterdam, The Netherlands, November 24, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that Kiadis will participate in the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference. Arthur Lahr, the company’s chief executive officer, will participate in a fireside chat and host one-on-one meetings with investors on Thursday, December 3, 2020.A recording of the fireside chat may be accessed by visiting the “For Investors” section of the Company’s website under the “Events and Presentations“. A replay of the fireside chat will be available for 90 days.Dutch Translation/Nederlandse vertalingKiadis...

Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies

PRESS RELEASE – REGULATED INFORMATION24 November 2020, 07:00 CETDisclosure of a transparency notificationMechelen, Belgium, 24 November 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that on 19 November 2020 it received a transparency notification dated 19 November 2020 (the ‘Notification’), indicating that on that date the shareholding of Debiopharm Innovation Fund S.A. decreased below the 3% notification threshold. Debiopharm Innovation Fund S.A. now holds 2.95% of the voting rights in Biocartis.The Notification...

PERSBERICHT – GEREGLEMENTEERDE INFORMATIE24 november 2020, 07:00 CETOpenbaarmaking van een transparantiekennisgevingMechelen, België, 24 november 2020 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag aan, overeenkomstig artikel 14, lid 1 van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt (de ‘Belgische Transparantiewet’), dat zij op 19 november 2020 een transparantiekennisgeving gedateerd 19 november 2020 (de ‘Kennisgeving’) heeft ontvangen waaruit blijkt dat de deelneming van Debiopharm Innovation Fund S.A. op die datum onder de kennisgevingsdrempel van 3% is gezakt. Debiopharm Innovation Fund S.A....

Awilco Drilling PLC reported contract revenue of USD 10.6 million (USD 6.4 million Q2), EBITDA USD 1.7 million (USD 1.5 million loss in Q2) and a net loss of USD 1.0 million (USD 4.6 million loss in Q2).Revenue efficiency was 100% during the standard day rate work in the quarter (Q2 fixed price work only).Operational uptime was 100% during the quarter during the standard day rate work in the quarter (Q2 fixed price work only).Contract backlog at the end of Q3 was approximately USD 15.2 million (USD 19.4 million Q2).Please see attached for the Q3 2020 report.A digital presentation will be held today, on 24 November 2020 at 12:00 UK time (13:00pm CET / 07:00 EST). The presentation will be available for download on the Investor Relations section (go to “Press Releases”) at www.awilcodrilling.com prior to the meeting. There will...

Sydney, Australia, 23rd November 2020 Sapphire Capitals is proud to announce the launch of a suite of trading applications for Stock and ETF traders around the world. These applications are aimed at providing the retail traders a systematic approach to Stock and ETF trading that is based on science, mathematics and statistics and help them make objective buy/sell trading decisions with confidence. These applications provide traders the ability to analyze all the Stocks in an Index or ETFs of the country and look back in history, for as many years they choose to find out the historical track record of recurrence of various price patterns. Rate of recurrence of these price patterns following an event is what provides traders the confidence or the probability of success. The suite of trading applications include Seasonality trading, Volume...